Luspatercept in Lower-Risk MDS

EP: 1.First- and Second-Line Treatment Options in Lower-Risk MDS

Now Viewing

EP: 2.Luspatercept in Lower-Risk MDS

EP: 3.Emerging Therapies for Lower-Risk MDS

Data from the following clinical trials are discussed:

• 3098: Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study
• 4408: Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept in the MEDALIST Study
• 1774: Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial
• 389: Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns